Pharmaceuticals

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sj?gren's Syndrome in China

 YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th,?Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sj?gren's syndr...

2025-08-13 17:57 1331

Prince Court Medical Centre Strengthens Malaysia's Position as a Global Healthcare Destination with First Kelly Procedure

KUALA LUMPUR, Malaysia, Aug. 13, 2025 /PRNewswire/ --?Prince Court Medical Centre has placedMalaysia firmly on the global medical tourism map by successfully performing the country's first Kelly procedure, an advanced reconstructive surgery for rare congenital urological conditions.

2025-08-13 15:16 1705

WuXi Biologics' WuXiUP? Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale

 * Building on its success in developing continuous production at pilot-scale with the?WuXiUP? platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading technologies,...

2025-08-12 17:00 1444

Intas & Accord signs Agreement to acquire Prothya Biosolutions

 AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based...

2025-08-11 21:41 2126

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

 SHANGHAI, Aug. 11, 2025 /PRNewswire/ --?Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim resul...

2025-08-11 17:11 1417

Philippines' AC Health partners with Singapore's ABC Impact in vision to transform health for every Filipino

 MANILA, Philippines, Aug. 11, 2025 /PRNewswire/ -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore-based impact investor dedicated to Asia and backed by Temasek Trust and Temasek. This strategic investment marks ABC Impact's entr...

2025-08-11 10:31 1538

RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

 YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple ad...

2025-08-08 17:50 1981

Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests

 Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring. HONG KONG, Aug. 8, 2025 /PRNewswire/ -- Codex Genetics, one of the leading precision diagnostics companies inHong Kong, today announced an exclusive colla...

2025-08-08 17:45 1958

WCC Biomedical@NACDS Total Store Expo: Advancing Microneedle Drug Delivery With WINMAP? Platform

TAIPEI, Aug. 8, 2025 /PRNewswire/ -- WCC Biomedical , a leader in novel drug delivery systems, will attend the upcomingNACDS Total Store Expo  (TSE), where it will spotlight its proprietary WINMAP? microarray patch (MAP) technology and launc...

2025-08-08 09:30 1402

Everest Medicines Announces Full Approval of NEFECON? in Taiwan

 SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the Taiwan Food and Drug Administrati...

2025-08-06 13:09 1287

Seegene Unveils CURECA? and STAgora? at ADLM 2025, Advancing the Next Stage of Diagnostics

 * Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, highlights progress toward fully automated and data-driven molecular testing * Introduction of CURECA?, the first fully unattended PCR automation system, and STAgora?, a real-time global data analytics platform * Technologies designed to sca...

2025-08-05 21:07 1700

Neopharma Technologies Appoints Exchange Listing to Manage U.S. IPO

 NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Neopharma Technologies Ltd (NTL), a leading MedTech company specializing in digital drug and impairment testing for workplace and public safety, has appointed Exchange Listing, LLC to manage its upcoming U.S. initial public offering (IPO), with plans to list...

2025-08-05 21:00 1156

Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion

 GUANGZHOU, China, Aug. 5, 2025 /PRNewswire/ --?Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock Exchange onAugust 7th. Through this integration, the company has effectively combined its expertise in drug R&D with the mature nationwid...

2025-08-05 15:34 1348

Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation

 BANGKOK, Aug. 4, 2025 /PRNewswire/ -- Chugai Pharma Taiwan (CPT), a subsidiary of Chugai Pharmaceutical Co., Ltd. inJapan, has been recognized in both the Social Empowerment and Green Leadership categories at the Asia Responsible Enterprise Awards (AREA) 2025. These recognitions highlight the com...

2025-08-05 13:02 2098

LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM CONSEQUENCES OF DANGEROUS 'BURN LINES' SOCIAL MEDIA TREND

 PARIS, Aug. 5, 2025 /PRNewswire/ --?A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young adults worldwide. The trend, which involves placing tape or stencils on the skin to intentionally burn patterned tan lines, has sparked wi...

2025-08-05 05:15 1338

Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

 BEIJING, Aug. 4, 2025 /PRNewswire/ --?Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canalic...

2025-08-04 14:05 1193

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

 SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially acce...

2025-08-04 09:28 1895

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 /PRNewswire/ --Alveolus Bio , a pioneering respiratory drug development bio...

2025-08-04 08:00 1630

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR

 SHANGHAI, Aug. 3, 2025 /PRNewswire/ --?Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial inChina for its LY03021, which was filed throughChina's Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NE...

2025-08-03 18:23 2215

Everest Medicines Expands Strategic Investment in I-MAB

 - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall resp...

2025-08-01 21:02 3065
123456 ... 190